Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Immunovia AB ( (SE:IMMNOV) ) is now available.
Immunovia has announced that the Centers for Medicare & Medicaid Services (CMS) finalized a national payment rate of $897 for its PancreaSure test, effective January 1, 2026. This milestone is crucial in Immunovia’s reimbursement strategy, allowing the company to begin billing insurance providers. The company is now focused on obtaining a Local Coverage Determination (LCD) by submitting clinical data to demonstrate the test’s validity and utility, aiming for completion in 2026.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes tests to detect proteins and blood-based antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to reach high-risk individuals. The USA is the largest market for pancreatic cancer detection, with an estimated 1.8 million high-risk individuals who could benefit from annual surveillance testing.
Average Trading Volume: 8,879,457
Technical Sentiment Signal: Sell
Current Market Cap: SEK164.2M
For a thorough assessment of IMMNOV stock, go to TipRanks’ Stock Analysis page.